search
Back to results

Iltamiocel Compared to Placebo for Chronic Fecal Incontinence in Females With Obstetric Injury (DigniFI)

Primary Purpose

Fecal Incontinence

Status
Not yet recruiting
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Iltamiocel
Placebo
Sponsored by
Cook MyoSite
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Fecal Incontinence focused on measuring Obstetric Trauma, Obstetric Injury, Cell Therapy, Anal Incontinence, Rectal Diseases, Intestinal Diseases, Gastrointestinal Diseases, Bowel Incontinence

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria: Adult female ≥ 18 years of age who has primary symptoms of fecal incontinence (FI) for at least 12 months. History of obstetric anal sphincter injury (e.g., episiotomy, perineal tear). Failed conservative treatment (e.g., dietary modification, antidiarrheal medications, pelvic floor muscle training, biofeedback) for at least 6 months prior to enrollment. Has a Cleveland Clinic Florida Incontinence Score (CCFIS) ≥9 at Baseline. Must be willing and able to comply with the study procedures, be mentally competent and able to understand all study requirements, and must agree to read and sign the informed consent form prior to any study-related procedures. Exclusion Criteria: Has an implanted stimulation neuromodulation system (sacral or tibial) and symptoms are unstable as determined by the physician. Is pregnant or planning to become pregnant within the next 2 years. Has known rectal sensory dysfunction (e.g., hypersensitivity or hyposensitivity). Has an obstetric anal sphincter injury (e.g., episiotomy, perineal tear) within 1 year previous to study enrollment. Patient BMI ≥ 35. Has a history of cancer in the colorectal or pelvic organs within 5 years prior to study enrollment. Any cancer that has undergone treatment within the past 12 months. Has an established diagnosis of inflammatory bowel disease (Crohn's disease, ulcerative colitis) or current intestinal stoma. Has grade III/IV hemorrhoids. Has chronic diarrhea at the time of Screening. Has chronic constipation at the time of Screening. Has significant pelvic floor prolapse, significant genitourinary prolapse beyond the introitus, significant symptomatic rectocele, or evidence of significant rectal evacuation disorder leading to post-defecatory leakage.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Placebo Comparator

    Arm Label

    Iltamiocel

    Placebo

    Arm Description

    Outcomes

    Primary Outcome Measures

    Changes in frequency of fecal incontinence episodes.

    Secondary Outcome Measures

    Full Information

    First Posted
    March 8, 2023
    Last Updated
    August 25, 2023
    Sponsor
    Cook MyoSite
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05776277
    Brief Title
    Iltamiocel Compared to Placebo for Chronic Fecal Incontinence in Females With Obstetric Injury
    Acronym
    DigniFI
    Official Title
    A Two-stage, Randomized, Controlled Trial Comparing the Safety and Efficacy of Iltamiocel With Placebo in the Treatment of Female Participants With Chronic Fecal Incontinence and a History of Obstetric Anal Sphincter Injury (DigniFI)
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    August 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    September 2023 (Anticipated)
    Primary Completion Date
    September 2026 (Anticipated)
    Study Completion Date
    September 2027 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Cook MyoSite

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    Yes
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    This study evaluates the efficacy and safety of a single injection of iltamiocel (300 x 10^6 cells) compared to a placebo in the reduction of fecal incontinence episode frequency in adult female participants with chronic fecal incontinence and a history of obstetric anal sphincter injury. Half of the participants will receive iltamiocel (injections with cells) and the other half will receive placebo.
    Detailed Description
    Chronic fecal incontinence (FI) is the recurrent unintended passage of mucus and/or liquid or solid stool for at least 6 months. Iltamiocel is an investigational cell therapy product that involves a medical procedure in which a participant's own muscle cells are collected, processed, and then injected into the tissues of the external anal sphincter. This is a double-blind randomized study, which means neither the participant, nor the study doctor will know which treatment group the participant will be in. Participants who are randomly chosen to receive injection with placebo will have the option to receive an injection with their cells after completion of the blinded portion of their study participation (12 months).

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Fecal Incontinence
    Keywords
    Obstetric Trauma, Obstetric Injury, Cell Therapy, Anal Incontinence, Rectal Diseases, Intestinal Diseases, Gastrointestinal Diseases, Bowel Incontinence

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 3
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantCare ProviderInvestigatorOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    200 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Iltamiocel
    Arm Type
    Experimental
    Arm Title
    Placebo
    Arm Type
    Placebo Comparator
    Intervention Type
    Biological
    Intervention Name(s)
    Iltamiocel
    Intervention Description
    Single external anal sphincter (EAS) injection of 300 x 10^6 cells.
    Intervention Type
    Other
    Intervention Name(s)
    Placebo
    Intervention Description
    Placebo control is the vehicle solution used for the study product.
    Primary Outcome Measure Information:
    Title
    Changes in frequency of fecal incontinence episodes.
    Time Frame
    12 Months

    10. Eligibility

    Sex
    Female
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Adult female ≥ 18 years of age who has primary symptoms of fecal incontinence (FI) for at least 12 months. History of obstetric anal sphincter injury (e.g., episiotomy, perineal tear). Failed conservative treatment (e.g., dietary modification, antidiarrheal medications, pelvic floor muscle training, biofeedback) for at least 6 months prior to enrollment. Has a Cleveland Clinic Florida Incontinence Score (CCFIS) ≥9 at Baseline. Must be willing and able to comply with the study procedures, be mentally competent and able to understand all study requirements, and must agree to read and sign the informed consent form prior to any study-related procedures. Exclusion Criteria: Has an implanted stimulation neuromodulation system (sacral or tibial) and symptoms are unstable as determined by the physician. Is pregnant or planning to become pregnant within the next 2 years. Has known rectal sensory dysfunction (e.g., hypersensitivity or hyposensitivity). Has an obstetric anal sphincter injury (e.g., episiotomy, perineal tear) within 1 year previous to study enrollment. Patient BMI ≥ 35. Has a history of cancer in the colorectal or pelvic organs within 5 years prior to study enrollment. Any cancer that has undergone treatment within the past 12 months. Has an established diagnosis of inflammatory bowel disease (Crohn's disease, ulcerative colitis) or current intestinal stoma. Has grade III/IV hemorrhoids. Has chronic diarrhea at the time of Screening. Has chronic constipation at the time of Screening. Has significant pelvic floor prolapse, significant genitourinary prolapse beyond the introitus, significant symptomatic rectocele, or evidence of significant rectal evacuation disorder leading to post-defecatory leakage.
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Cook MyoSite
    Phone
    412-963-7380
    Email
    DigniFIStudy@CookMyoSite.com

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Iltamiocel Compared to Placebo for Chronic Fecal Incontinence in Females With Obstetric Injury

    We'll reach out to this number within 24 hrs